Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Serum uric acid and knee osteoarthritis in community residents without gout: a longitudinal study
Recent trials confirm complementary kidney protection by both drug classes
Receptor-target and efficacy comparison: GLP-1 class agents | Agent | GLP-1 | GIP | Glucagon | Approval | Best trial weight loss | |---|---|---|---|---|---| | Liraglutide (Saxenda) | Yes | No | No | FDA-approved | 8.0% at 56 weeks (SCALE) | | Dulaglutide (Trulicity) | Yes | No | No | T2D only | 3.0 kg mean at 52 weeks | | Semaglutide (Wegovy) | Yes | No | No | FDA-approved | 14.9% at 68 weeks (STEP-1) | | Tirzepatide (Zepbound) | Yes | Yes | No | FDA-approved | 20.9% at 72 weeks (SURMOUNT-1) | | Retatrutide | Yes | Yes | Yes | Investigational | 24.2% at 48 weeks (Phase 2) | Liraglutide and Dulaglutide: Where They Fit Now Liraglutide (Saxenda, 3 mg once daily subcutaneous) was the first GLP-1 agonist approved specifically for obesity in the United States
Regarding renal effects, the evidence of SGLT2is in preventing kidney failure is more abundant than for GLP-1RAs, which showed a beneficial effect on albuminuria but not on hard kidney endpoints
Strkere Regeneration Weniger Muskelschden und schnellerer Erholungsprozess durch antioxidative Wirkung
US$ 28.55
US$ 23.36
US$ 21.26
US$ 20.43
